Live Biotherapeutics Drug Discovery Services for Nonalcoholic Fatty Liver Disease (NAFLD)

Probiotics have been demonstrated to be effective in the prevention and reversion of nonalcoholic fatty liver disease through several pathways. Creative Biolabs provides a range of optimized services to support your probiotic-based drug discovery for the treatment of nonalcoholic fatty liver disease.

Introduction to Nonalcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) refers to a wide spectrum of hepatic conditions characterized by excessive fat accumulation in the liver without alcohol use. As the most common cause of chronic liver disease, NAFLD is becoming the most prevalent and intractable health concern all over the world with increased morbidity, which is affecting 25% proportion of the worldwide population and ~30% of Americans, respectively.

Although multiple factors, such as obesity, insulin resistance, or type 2 diabetes, metabolic disorders, hypertension, oxidative stress, have been indicated to be strongly associated with the pathogenesis of NAFLD, the specific pathways and mechanisms are still being explored. NAFLD can be manifested as mild non-alcoholic fatty liver, which can progress to more severe forms, including non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma, if not well managed.

Factors implicated in NAFLD. Fig.1 Factors implicated in NAFLD. (Mann, 2016)

Therapeutic Role of Probiotic in the NAFLD Treatment

In healthy individuals, over 1000 species of microorganisms colonized in the digestive tract live synergistically with the host and exert protective and beneficial physiological effects. Once this microbiome composition balance is disturbed, a series of negative effects and illnesses will be caused to the body. Among those potential risk factors, it has been confirmed that gut microbiota and its metabolites play a non-negligible role in the pathogenesis of NAFLD. Gut microbiota dysbiosis has been pointed out to cause inflammation and steatosis in the liver through the gut-liver axis.

The proposed role of probiotics in NAFLD therapy. Fig.2 The proposed role of probiotics in NAFLD therapy. (Perumpail, 2019)

Numbers of animal experiments have shown that probiotics can re-establish a healthy gut microbiome composition and effectively reverse chronic liver damage. For example, the supplement of probiotic Lactobacillus johnsonii BS15 was able to effectively prevent and treat NAFLD induced by a high-fat diet by protecting mice from hepatic steatosis and hepatocyte apoptosis, inhibiting insulin resistance and mitochondria abnormalities, and enhancing the liver antioxidant defense. VSL#3, a multi-strain formulation consisting of eight strains of bacteria (Lactobacillus casei, Bifidobacterium breve, Streptococcus thermophiles, etc.), has been validated that have anti-inflammatory, anti-fibrotic effects in the liver, as well as meliorate hepatic insulin resistance and fatty acid beta-oxidation. All these studies show that probiotics are promising therapeutic choices for NAFLD treatment.

What Can We Do for You?

Founded in the USA in 2005, Creative Biolabs has developed into a leader in the field of drug discovery over years’ expansion. And probiotics-based live biotherapeutics has gradually come into view due to their favorable therapeutic effects. We have successfully developed an advanced technology platform and standard workflow to offer comprehensive probiotic products and analytical and qualification services for a variety of disease treatment.

Please contact us without hesitation. Our solution is tailored to meet your special requirements.

References

  1. Mann, J. P., et al. How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease? Frontiers in Endocrinology. 2016, 7: 145.
  2. Perumpail, B.J., et al. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases. 2019, 7: 27.
  3. Xin, J., et al. Preventing non-alcoholic fatty liver disease through Lactobacillus johnsonii BS15 by attenuating inflammation and mitochondrial injury and improving gut environment in obese mice. Applied Microbiology and Biotechnology. 2014, 98: 6817-6829.

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Live Biotherapeutics Drug Discovery

Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Contact us

Contact us

Copyright © 2022 Creative Biolabs. All Rights Reserved.

Inquiry Basket